Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of midazolam on restlessness and agitation after electroconvulsive therapy
IRCT20170108031818N3Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of midazolam in Restlessness and agitation, sponsored by Golestan University of Medical Sciences. Primary endpoints: Occurrence of restlessness and Occurrence of agitation. Started Feb 2023; status: completed.
02
Drugs
midazolam
03
Conditions
Restlessnessagitation
Beyond the preview
Go deeper on IRCT20170108031818N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170108031818N3.